Martin Rossor (MRC), Giovanni B. Frisoni (MDS), Mario Masellis (CIHR)

Recent advances in molecular biology and neuropathology of frontotemporal lobar degeneration (FTLD) have yet to be translated into effective, disease-modifying therapies. Further progress toward this goal will depend on largescale collaborative efforts that harness resources and expertise across specialist centres. The proposed programme will develop and evaluate the feasibility of a platform for mounting future large-scale natural history studies of FTLD and for conducting clinical trials of disease-modifying interventions.